All In Biotech

Drug Trial Radar · NCT03684811

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Last checked: Nov 20, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

93

Actual

Start

Nov 1, 2018

Primary completion

May 24, 2021

Study completion Jun 13, 2022

Sponsor

Lead sponsor
Forma Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas. The study is divided into two parts: single agent FT-2102 followed by combination therapy. Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or altered dose schedules may be explored. Part 2: An open-label study of FT-2102 in combination with other anti-cancer agents. Patients will be enrolled across 4 different disease cohorts, examining the effect of FT-2102 + azacitidine (glioma and chondrosarcoma), FT-2102 + nivolumab (hepatobiliary tumors), and FT-2102 + gemcitabine/cisplatin (intrahepatic cholangiocarcinoma). There will be a safety lead-in followed by a Phase 2 evaluation in up to four cohorts of patients.

Conditions

  • Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)
  • Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
  • Cohort 3a and 3b: Chondrosarcoma
  • Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
  • Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations

Interventions

  • FT-2102Drug

    FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.

  • AzacitidineDrug

    Azacitidine will be administered per the site's standard of care.

  • NivolumabBiological

    Nivolumab will be administered per the site's standard of care.

  • Gemcitabine and CisplatinDrug

    Gemcitabine and cisplatin will be administered per the site's standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Dose Limiting Toxicity (DLT)Time frame: Day 1-28
  2. Overall Response Rate (ORR)Time frame: While on treatment

Locations

26 sites in 6 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson

    Gilbert, Arizona

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • University of Miami, Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Northwestern University, Lurie Comprehensive Cancer Center

    Chicago, Illinois

  • University of Iowa, Holden Comprehensive Cancer Institute

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Columbia University Medical Center

    New York, New York

  • Baylor Scott and White Medical Center

    Temple, Texas

  • University of Utah, Huntsman Cancer Hospital

    Salt Lake City, Utah

  • Medical College of Wisconsin, Froedtert Hospital

    Milwaukee, Wisconsin

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Centre de Lutte Contre Cancer (CLCC) - Institute Bergonie

    Bordeaux, France

  • Centre de Lutte Cancre (CLCC) - Lyon

    Lyon, France

  • Hospital de la Timone

    Marseille, France

  • Institut Gustave Roussy Cancer Campus

    Villejuif, France

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Vall D'Hebron University Hospital

    Barcelona, Spain

  • Cancer Research Beatson Institute

    Glasgow, United Kingdom

  • The Royal Marsden Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.